Drug Profile
Research programme: KIBRA modulators - SYGNIS Pharma
Latest Information Update: 27 Dec 2012
Price :
$50
*
At a glance
- Originator Amnestix
- Developer SYGNIS Pharma
- Class Peptides
- Mechanism of Action Intracellular signalling peptide and protein modulators; Phosphoprotein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Cognition disorders
Most Recent Events
- 20 Dec 2012 Discontinued for Alzheimer's disease in Germany (unspecified route)
- 20 Dec 2012 Discontinued for Cognition disorders in Germany (unspecified route)
- 25 Jul 2012 SYGNIS Pharma is seeking partnering opportunities for the development of its KIBRA modulators programme. http://www.sygnis.de/